Abstract:Glioblastoma multiforme (GBM) is the most aggressive and common malignant primary brain tumor. Patients with GBM often have poor prognoses, with a median survival of ∼15 months. Enhanced understanding of the molecular biology of central nervous system tumors has led to modifications in their classifications, the most recent of which classified these tumors into new categories and made some changes in their nomenclature and grading system. This review aims to give a panoramic view of the last 3 years' findings in glioblastoma characterization, its heterogeneity, and current advances in its treatment. Several molecular parameters have been used to achieve an accurate and personalized characterization of glioblastoma in patients, including epigenetic, genetic, transcriptomic and metabolic features, as well as age- and sex-related patterns and the involvement of several noncoding RNAs in glioblastoma progression. Astrocyte-like neural stem cells and outer radial glial-like cells from the subventricular zone have been proposed as agents involved in GBM of IDH-wildtype origin, but this remains controversial. Glioblastoma metabolism is characterized by upregulation of the PI3K/Akt/mTOR signaling pathway, promotion of the glycolytic flux, maintenance of lipid storage, and other features. This metabolism also contributes to glioblastoma's resistance to conventional therapies. Tumor heterogeneity, a hallmark of GBM, has been shown to affect the genetic expression, modulation of metabolic pathways, and immune system evasion. GBM's aggressive invasion potential is modulated by cell-to-cell crosstalk within the tumor microenvironment and altered expressions of specific genes, such as ANXA2, GBP2, FN1, PHIP, and GLUT3. Nevertheless, the rising number of active clinical trials illustrates the efforts to identify new targets and drugs to treat this malignancy. Immunotherapy is still relevant for research purposes, given the amount of ongoing clinical trials based on this strategy to treat GBM, and neoantigen and nucleic acid-based vaccines are gaining importance due to their antitumoral activity by inducing the immune response. Furthermore, there are clinical trials focused on the PI3K/Akt/mTOR axis, angiogenesis, and tumor heterogeneity for developing molecular-targeted therapies against GBM. Other strategies, such as nanodelivery and computational models, may improve the drug pharmacokinetics and the prognosis of patients with GBM.

Current progress of anti‐PD‐1/PDL1 immunotherapy for glioblastoma (Review)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma

Current State of Immune Checkpoints Therapy for Glioblastoma

Immunotherapy for glioblastoma: current state, challenges, and future perspectives

Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma

The Advances in Targeted Therapy and Immunotherapy for Glioblastoma: Basic Research and Clinical Trials

Research progress and challenges of the PD-1/PD-L1 axis in gliomas

Advances in Nanotechnology-Based Immunotherapy for Glioblastoma

Immunological challenges and opportunities in glioblastoma multiforme: A comprehensive view from immune system lens

Application Prospect of Peptide-Modified Nano Targeting Drug Delivery System Combined with PD-1/PD-L1 Based Immune Checkpoint Blockade in Glioblastoma.

From promise to progress: the dynamic landscape of glioblastoma immunotherapy

Immunotherapy of Glioblastoma: Recent Advances and Future Prospects

Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives

Emerging therapies for glioblastoma: current state and future directions

Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma

Prospects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma

Immune Checkpoint in Glioblastoma: Promising and Challenging

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance

An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma